Skip to main content
OpenTrials
Completed

NCT Number: NCT03810378

Contrasting Ketogenic and Mediterranean Diets in Individuals With Type 2 Diabetes and Prediabetes: The Keto-Med Trial

The objective of this study is to compare two metabolically distinct diets, WFKD vs Med-Plus, in order to examine the potential benefits, and unintended consequences, of going beyond a focus on maximally avoiding added sugars and refined grains, to also avoiding legumes, fruits, and whole grains.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University

Stanford, California, 94305, United States

About this study

The proposed randomized clinical trial will investigate differential population-specific effects of two low-carbohydrate (low-carb) diet patterns, addressing a gap in the evidence base in this area that will lead to 1) improved treatment strategies for common adverse clinical conditions, 2) improved health for these individuals, and 3) long-term decreases in health care costs. This impactful research will advance the field of personalized and precision medicine.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18
  • Diagnosed with type 2 diabetes mellitus, OR prediabetes (defined as HbA1c </= 5.7% OR Fasting Glucose of >100 mg/dL)

Identify exclusion criteria.

  • Weight < 110 lb
  • BMI > 40
  • LDL-C >190 mg/dL
  • Blood pressure: SBP > 160 mmHg OR DBP: > 90 mmHg

Exclusion criteria

  • Weight < 110 lb
  • BMI ≥ 40
  • LDL-C >190 mg/dL
  • Systolic blood pressure (SBP) > 160 mmHg OR Diastolic blood pressure (DBP) > 90 mmHg
  • Diagnosed with type 1 diabetes or history of ketoacidosis
  • Uncontrolled and untreated diabetes (by discretion of study physician)
  • Active cardiovascular disease (in past year with myocardial infarction, coronary stent or bypass surgery)
  • Kidney disease (eGFR less than 50 mL/min per 1.73 m2)
  • Liver disease (liver transaminase higher than 3 times the normal range for the laboratory)
  • Symptomatic gallstones
  • History of bariatric surgery
  • Anemia
  • Taking any of the following medications in past 3 months: SGLT-2 inhibitors, GLP-1 receptor agonist, Insulin, Amylin analog, Alpha-glucosidase inhibitor, Dopamine agonist, Bile acid sequestrant.
  • Taking any medications for weight loss
  • History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision
  • Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
  • Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or > 14 drinks/week.
  • Women: Pregnant currently or planning to become pregnant during the course of the study, and/or breastfeeding
  • Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products
  • Regular use of prescription opiate pain medication

Treatment and study plan

Mediterranean Diet (Med-Plus)

Behavioral

Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).

Well-Formulated Ketogenic Diet (WFKD)

Behavioral

Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).

Primary outcomes

  1. Hemoglobin A1c (HbA1c)

    Time frame: Baseline and 12 weeks

    Change from baseline in HbA1c at 12 weeks of each phase

Secondary outcomes

  1. Microbiota composition

    Time frame: Baseline and 12 weeks

    Change from baseline in alpha diversity at 12 weeks of each phase. We will be using number of observed sequence variants ("species") determined by standard 16S rRNA amplicon sequencing (V3-V5 region followed by DADA2 to define error-corrected sequence variants) as our primary metric of alpha diversity. Higher alpha diversity is better. The units are the # of sequence variants.

  2. Microbiota function

    Time frame: Baseline and 12 weeks

    Change from baseline in composite of short-chain fatty acids (SCFA) concentration (ug/g stool: acetate + propionate + butyrate) at 12 weeks of each phase.

  3. LDL Cholesterol

    Time frame: Baseline and12 weeks

    Change from baseline in LDL cholesterol at 12 weeks of each phase.

  4. HDL Cholesterol

    Time frame: Baseline and 12 weeks

    Change from baseline in HDL cholesterol at 12 weeks of each phase.

  5. Triglycerides

    Time frame: Baseline and 12 weeks

    Change from baseline in triglycerides at 12 weeks of each phase.

  6. Fasting insulin

    Time frame: Baseline and 12 weeks

    Change from baseline in fasting insulin at 12 weeks of each phase.

  7. Blood pressure

    Time frame: Baseline and 12 weeks

    Change from baseline in blood pressure at 12 weeks of each phase.

Other outcomes

  1. Satisfaction with WFKD and Med-Plus diets

    Time frame: Baseline and 12 weeks

    Average satisfaction level with meals at 12 weeks of each phase (WFKD compared to Med-Plus phase) using a 5-point Likert scale (1=not at all satisfied; 2=slightly satisfied; 3=moderately satisfied; 4=very satisfied; 5=extremely satisfied).

  2. Adherence to diet protocols

    Time frame: Baseline and 12 weeks

    Adherence to diet protocols 12 weeks of each phase in subjects with Diabetes compared to subjects with prediabetes, according to 3-day food records.

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Important dates

Study start
2019
Primary completion
2020
Study completion
2020
First posted
Jan 18, 2019
Registry last updated
Feb 21, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.